The patent was awarded based on FDA-authorised clinical study, which showed that the non-toxic dietary supplement (PHC) contributed to healthy outcome for men with recurrent prostate cancer.
The study found that prostate specific antigen (PSA) stabilized in 83% of subjects with recurrent prostate cancer who took three PHC capsules daily and in nearly 30% of subjects PSA actually declined.
The PHC developed by oncologist and prostate cancer researcher Jacek Pinski, contains EGCG from green tea extract, selenium, lycopene, minerals, herbs, vitamins and isoflavanoids that reduce the risk of prostate disease in men ages of 40 and older.
Oncologist and prostate cancer researcher Jacek Pinski said PHC is designed for use as a complement to existing prostate cancer treatments.
"The formula is based on extensive research, and evidence of its effectiveness continues to accumulate,” Pinski added.
”The recent patent award reinforces the promise of this breakthrough dietary supplement and our commitment to forward-thinking treatment plans for men with recurrent prostate cancer."